

RESEARCH

Open Access

The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study

Fahimeh Ramezani Tehrani^{1*}, Masoumeh Simbar¹, Maryam Tohidi¹, Farhad Hosseinpanah², Fereidoun Azizi¹

Abstract

Background: Despite the heavy burden and impact of the polycystic ovary syndrome (PCOS) in reproduction and public health, estimates regarding its prevalence at community levels are limited. We aimed to ascertain prevalence of PCOS in a community based sample using the National Institute of Health (NIH), the Rotterdam consensus (Rott.) and the Androgen Excess Society (AES) criteria.

Methods: Using the stratified, multistage probability cluster sampling method, 1126 women were randomly selected from among reproductive aged women of different geographic regions of Iran. PCOS were diagnosed using universal assessment of ultrasonographic parameters, hormonal profiles and clinical histories.

Results: The mean +/- SD of age of study population was 34.4 +/- 7.6 years. Estimated prevalence of idiopathic hirsutism was 10.9% (95% CI: 8.9-12.9%); 8.3% of women had only oligo/anovulation and 8.0% had only polycystic ovaries. The prevalence of PCOS was 7.1% (95% CI: 5.4-8.8%) using the NIH definition, 11.7% (95% CI: 9.5-13.7%) by AES criteria and 14.6% (95% CI: 12.3-16.9%) using the Rott definition.

Conclusions: At community level, widespread screening of Rotterdam criteria will increase the estimated prevalence of PCOS over twofold. Establishing an explicit and contemporaneous method for definition and screening of each PCOS criteria has important investigational implications and increase the comparability of published research.

Background

Polycystic ovary syndrome (PCOS) is the most common gynecological endocrinopathy [1,2]. Women with PCOS are at increased risk of reproductive problems including infertility, endometrial cancer, late menopause [3-6] and also metabolic aberrations, including insulin resistance, type 2 diabetes mellitus, dyslipidemia and cardiovascular diseases [7-10].

Despite the heavy burden and impact of the polycystic ovary syndrome (PCOS) in reproduction and public health, estimates regarding its prevalence are limited; considering the controversy regarding its diagnostic criteria and difficulties in conducting prevalence studies at community levels, data on its current prevalence are

questionable [11]. The reported prevalence of PCOS ranges between 2.2% to 26% in various countries, depending on the recruitment process of the study population, the criteria used for its definition and the method used to define each criterion [1,11-21]. Recruitment strategy affects the types of subjects enrolled in a study; e.g. recruiting the subjects using the promise of a health evaluation [19] may potentially bias the results toward disease-carrying individuals. Considering that the Rott. versus NIH criteria increases the PCOS prevalence by 1.5-2 times [21,22], its prevalence may be influenced by using various definitions and the screening method for identification of androgen excess or ovulatory dysfunction [11,14,23]; unless universal screening for hyperandrogenemia or subclinical oligo/anovulation is conducted, identification of these conditions can easily be overlooked [24,25]. There are significant ethnic and racial variations in the clinical presentation of PCOS [26,27] and the Ferriman-Gallwey (F-G) score of

* Correspondence: ramezani@endocrine.ac.ir

¹Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Full list of author information is available at the end of the article

hirsutism may be unreliable for identifying androgen excess in some ethnic groups [28]. East Asians are typically less hairy than Euro-Americans, which may be explained by low levels of 5 α -reductase activity in the skin of those women [29].

To the best of our knowledge there is no population based study that estimates the prevalence and clinical characteristics of PCOS in the Eastern Mediterranean Region. The objective of the present study was to determine the prevalence of PCOS under the NIH, Rott, and the AES criteria, in a well-defined, non-selected population of Iranian reproductive aged women, using universal assessment of ultrasonographic parameters, hormonal profiles and clinical histories.

Methods

Study subjects and the sampling method

Sample size was calculated based on these parameters: $P = 0.085$ [5], $\alpha = 0.95$, $d = 0.025$, cluster design effect = 2 and a non response rate = 0.15. A stratified, multistage probability cluster sampling method, with a probability in proportion to size procedure, was used. The frame for the selection of the sampling units was based on the Iranian household lists available in the Health Department. The information regarding the age, sex, and marital status of each family member is available in this list and updated annually. Selecting the cluster was made systematically and the starting points for the survey in each cluster were determined centrally.

A total of 1126 women, aged 18-45 years, were recruited from among reproductive aged women living in urban areas of four randomly selected provinces of different geographic regions i.e. Ghazvin (Central), Kermanshah (East), Golestan (North) and Hormozgan (South). The age and sex distribution of the population of these provinces is representative of national general population based on 2006 national population and housing census of Iran. Menopausal women, those who had undergone hysterectomy or bilateral oophorectomy and pregnant women were excluded ($n = 90$). To minimize the effect of treatment bias, all other women, regardless of hormonal therapy including insulin sensitizers and oral contraceptive pills were included, but their hormonal and biochemical parameters were not considered for statistical analysis.

Study protocol

Pairs of trained staff members of local medical universities/schools (midwives) served as interviewers, and a trained supervisor monitored the process in each district. The interviewers, thoroughly explained the purpose and procedure of the study to subjects and obtained their consent and a checklist questionnaire, based on the inclusion and exclusion criteria, was

completed at subjects' homes ($n = 1126$). Women who met the inclusion criteria ($n = 1036$) were invited to a referral clinic in each province for a comprehensive interview and physical exam. Ninety seven eligible women who signed the inform consent did not come to the clinics, as a result the response rate of our study was 91%. For those eligible women who referred to clinics ($n = 939$) a standard questionnaire including demographic and reproductive variables, with emphasis on regularity of menstrual cycle, gynecological history, hyperandrogenic symptoms, family history of irregular menstrual cycle and hirsutism was completed, during face-to-face interviews by trained midwives under supervision of a gynecologist. The hirsutism scores were assessed using the modified Ferriman-Gallwey (mFG) scoring method [30]. Acne was scored based on its number, type, and distribution [31]. The menstrual cycle of subjects on hormonal medication was evaluated by questioning about menstrual regularity before starting medication. To maximize the accuracy of hirsutism scoring, subjects with an initial mF-G score more than 3 per the study midwives and/or those women with menstrual dysfunction were reexamined by a single gynecologist in each province.

All participants underwent clinical examinations, where body weight, height, waist (WC), hip circumferences (HC) and blood pressure were measured. Body mass index was calculated as weight in kilograms divided by the height in meters squared (kg/m^2).

An overnight fasting venous blood sample was obtained from each subject on the second or third day of their spontaneous or progesterone induced menstrual cycles ($n = 929$). All sera were stored at -80°C until the time of measurements.

All of the study subjects were invited for transvaginal ($n = 760$) or transabdominal ($n = 169$) ultrasound scans of the ovaries, which were performed using the 3.5-MHz transabdominal and 5-MHz transvaginal transducer by an experienced sonographer in each province and all scans were assessed by a single sonographer. Ultrasound was performed as the same day as the blood samples were collected.

Measurements

Dehydroepiandrosterone sulfate (DHEAS), 17-hydroxyprogesterone (17OH-P), Total testosterone (TT) and Androstendion(A4) were measured by enzyme immunoassay (EIA), (Diagnostic biochem canada Co. Ontario, Canada). Sex Hormone Binding Globulin (SHBG) was measured by immunoenzymometric assay (IEMA), (Merckodia, Uppsala, Sweden). All ELISA tests were performed using Sunrise ELISA reader (Tecan Co. Salzburg, Austria).

Luteinizing hormone (LH), Follicle stimulating hormone (FSH), Prolactin (PRL), and Thyroid stimulating hormone

(TSH) was measured by immunoradimetric assay (IRMA), (Izotop, Budapest, Hungary) using gamma counter Wallac Wizard, Turku, Finland).

It has been shown that in women the free androgen index (FAI) has a good correlation with free testosterone measured by physical separation method [32]; therefore FAI was calculated using the formula $[TT \text{ (nmol/L)} \times 100/\text{SHBG} \text{ (nmol/L)}]$. The intra- and inter-assay coefficients of variation for TT were 5.6% and 6.6%; for DHEAS: 2.0% and 5.1%; for 17 OH-P: 4.8% and 6.8%; for SHBG: 1.2% and 5.7%; for A4: 2.2% and 3.5%; for LH: 3% and 5.8%; for FSH: 3.5% and 4%; for TSH: 1.7% 3.4%, and for PRL, they were 2.1% and 4.1%.

Definitions

We defined PCOS in our study using the NIH [33], Rott. [34] and AES criteria [35]. Using the NIH criteria, PCOS was defined as the combination of chronic anovulation (ANOVU) and clinical hyperandrogenism and/or hyperandrogenemia (HA). By Rott. criteria, PCOS was defined by the presence of two or more of the following: 1) Oligo/anovulation (ANOVU), 2) Hyperandrogenemia and/or hyperandrogenism (HA), and 3) Polycystic ovaries (PCO). Using the AES definition, PCOS was diagnosed by the presence of clinical and/or biochemical hyperandrogenism (HA) with ovarian dysfunction defined as oligo/anovulation (ANOVU) and/or polycystic ovaries (PCO). Hyperprolactinemia, thyroid dysfunction, and nonclassic 21-hydroxylase deficiency were excluded in all of the women who achieved the other criteria for the diagnosis of PCOS.

ANOVU was considered as vaginal bleeding episodes at no less than 35-day intervals [36,37]. HA was determined as clinical hyperandrogenism (CH) and/or biochemical hyperandrogenemia (BH). CH was defined by the presence of hirsutism ($\text{mF-G} \geq 8$) [30], acne, or the presence of androgenic alopecia. BH was detected by FAI and/or DHEAS and/or A4 level, above the upper 95th percentile for the 362 women studied, who were not on any hormonal medication and had no clinical evidence of hyperandrogenism, ANOVU and PCO. Specifically, the upper normal limits were total T = 0.88 ng/ml, A4 = 2.3 ng/ml, DHEAS = 246 $\mu\text{g/dL}$ and FAI = 5.47

PCO was diagnosed by the presence of 12 or more follicles in each ovary, measuring 2-9 mm in diameter and/or increased ovarian volume (10 cm^3) [38,39].

Idiopathic hirsutism (IH) was defined as hirsutism without ANOVU and/or PCO [24]. BH plus hirsutism was defined as hirsutism with BH without PCOS, using the Rott. definition [40].

Primary infertility was defined as the having the history of trying to conceive for at least one year without success despite of regular sexual intercourse, no use of contraception and no previous pregnancy.

Statistical analysis

Continuous variables were checked for normality using the one-sample Kolmogorov-Smirnoff test; they are expressed as mean \pm standard deviation and/or median and interquartile ranges, as appropriate. The categorical variables are expressed as percentages. Distributions between groups are compared using the Kruskal-Wallis test, followed with Mann-Whitney test with Bonferroni correction for pair wise comparison. The categorical variables are compared using the Pearson's χ^2 test. Data analysis was performed using the SPSS 15.0 PC package (SPSS Inc., Chicago, IL).

The ethical review board of the Research Institute for Endocrine Sciences has approved the study proposal and informed consent was obtained from all subjects.

Details of Ethics Approval


The ethical review board of the Research Institute for Endocrine Sciences has approved the study proposal (approved number: 47854 Date: 15/12/2007) and informed consent was obtained from all subjects.

Results

A study checklist was completed for 1126 women, aged 18-45 years. Figure 1 outlines the data collection procedure. Of 1036 women who met our inclusion criteria, 929 ones completed the study procedure. The mean age of study population was 34.4 years. There was 65 women who used oral contraceptive pill, 61 did so solely for the purpose of contraception.

Of a total of 929 women, 423(45.5%) subjects were eumenorrheic and did not have HA and or PCO (normal), 205 (22.1%) women had only HA and overall, 3.5% of all women had acne. Seventy-seven (8.3%) women had only ANOVU and 74 (8.0%) women had only PCO in ultrasonography; the estimated prevalence of IH was 10.9% (95% CI: 8.9-12.9%) (Figure 1). Out of 929 study participants, 136 women met Rott criteria therefore the prevalence of PCOS using Rott. criteria was 14.6% (95% CI: 12.3- 16.9%). There was 109 women with PCOS based on AES criteria, as a result the prevalence of PCOS was 11.7% (95% CI: 9.5- 13.7%) using AES definition. Out of 929 study participants, 66 women met NIH criteria therefore the prevalence of PCOS using NIH criteria was 7.1% (95% CI: 5.4 -8.8%). There were not any suspicious cases of congenital adrenal hyperplasia, androgen-secreting tumors and Cushing's syndrome based on physical exam and hormonal assessment.

Basic, reproductive and metabolic characteristics of those who had various phenotypes of PCOS using Rott. criteria in comparison to normal women are shown in Table 1. Compared to their normal counterparts, the prevalence of primary infertility was about two to three times higher among women with PCOS. The familial



history of androgen excess or ANOVU was more prevalent in group 1 (ANOVU+ HA +/-PCO) phenotype in comparison to normal subjects (Table 1).

From among 314 (33.8%) women who had HA in our study, 109 had PCOS using Rott. definition (Figure 1). Of these PCOS women, 54 ones had only CH, 18 women had both CH and BH and the reminding 37 had pure BH (14 pure FAI excess, 6 pure A₄ excess, 2 pure DHEAS excess and 15 mixed androgen excess). Of these 37, 8 women would possibly have remained undiagnosed, had we not assessed the serum concentrations of androgens in women without oligo/ovulation.

Discussion

The prevalence of PCOS was 7.1% (95% CI: 5.4 -8.8%) using the NIH definition, 11.7% (95% CI: 9.5- 13.7%) by AES criteria and 14.6% (95% CI: 12.3- 16.9%) using the Rott. criteria in our sample of an Iranian population. To the best of our knowledge there is no study in the Eastern Mediterranean Region that estimates the prevalence

and clinical characteristics of PCOS among an unselected population.

The reported prevalence of PCOS in various geographic regions ranges between 2.2% to 26% [1,11-21]. In Southern China the prevalence was 2.4% among 915 women recruited through the offer of a free medical examination using Rott criteria [14]; it was 6.5% among 154 white blood donor women in Spain using NIH criteria [18], In the study by Azziz et al. of women undergoing a preemployment physical examinations in the United States, the cumulative prevalence of PCOS was 6.6% using the NIH definition [1]; the prevalence of PCOS using Rott. definition was reported to be 17.8% among 978 women, who were recruited in a retrospective birth cohort study in South Australia [11]. Among 157 women with type 2 diabetes in Esfahan-Iran, the prevalence of PCOS was 8.2% [41].

The PCOS prevalence depends on the recruitment process of the study population and criteria used for its definition; in the present study considering the Rott.

Table1 The characteristics of various phenotypes of PCOS using Rotterdam criteria

Phenotype characteristic	Group 1 (n = 66) ANOVU+ HA ± PCO	Group2 (n = 43) HA + PCO	Group3 (n = 27) ANOVU + PCO	Normal (n = 423)
Age (years)	31.0 (25.8-37.3)*	30.0 (25.0-40.0)*	35.0 (28.0-39.0)	36.0 (30.0-41.0)
BMI (kg/m2)	27.0 (25.8-37.3)	25.0 (21.6-29.2)	25.6 (23.0-31.2)	26.4 (23.1-29.4)
WHR	0.81 (0.76-0.85)	0.78 (0.75-0.85)	0.83 (0.78-0.86)	0.81 (0.76-0.85)
Systolic Blood Pressure (mm/Hg)	110.0 (100.0-120.0)	100.0 (105.0-110.0)	110.0 (100.0-110.0)	110.0 (100.0-120.0)
Diastolic Blood Pressure (mm/Hg)	70.0 (60.0-80.0)	70.0 (60.0-70.0)	70.0 (60.0-70.0)	70.0 (60.0-80.0)
% Women with history of Primarily infertility	27.3*	21.6*	31.0*	10.6
% women with family history of HA	42.4*	20.9	11.1	14.0
% women with family history of ANOVU	36.4*†‡	14.0	22.2	19.0
LH/FSH Ratio	0.77 (0.46-1.04)	0.64 (0.45-1.0)	0.69 (0.5-1.1)	0.6 (0.43-0.86)
Total T (ng/ml)	0.75 (0.57-0.88) *‡	0.81 (0.52-0.93) *††	0.41 (0.29-0.53)	0.51 (0.32-0.68)
FAI	4.7 (3.1-6.9) *‡	4.9 (3.6-7.1) *††	2.2 (1.3-2.8)	2.6 (1.5-3.7)
A4 (ng/ml)	5.8 (5.1-6.9) *‡	2.1 (1.8-2.5) *††	1.1 (0.9-2.0)	1.1 (0.9-1.7)
DHEAS (µg/Dl)	196.1 (149.5-238.1) *‡	200.5 (138.9-248.0) *††	141.5 (45.7-186.7)	138.0 (58.3-192.8)
SHBG (nmol/L)	54.8 (42.7-70.7) *	54.4 (45.0- 67.1) *	62.6 (49.1-88.1)	67.2 (53.4-92.4)

Values are given as median (Inter quartile range), †The hormonal and biochemical assessments of those women who use insulin sensitizers and/or oral contraceptive pills were not included for statistical analysis. * = versus normal group, p < 0.008, † = Group1 versus Group2, P < 0.008; ‡ = Group 1 versus Group 3; †† = Group2 versus Group3, p < 0.008; WHR, waist to hip ratio; Normal group, eumenorrheic and without HA and PCO; ANOVU, oligo/anovulation; HA, hyperandrogenemia and/or hyperandrogenism; PCO, polycystic ovaries; DHEAS, Dehydroepiandrosterone sulfate; Total T, Total testosterone; A4, Androstendion; SHBG, Sex Hormone Binding Globulin; FAI, Free androgen index.

versus NIH criteria increased its prevalence by 2 times, as reported before [21,22] [42-44]. Furthermore the definition of each criteria and its screening method has a considerable impact on PCOS prevalence at the community level [1,11,16]. There was not any agreement regarding the cut off value for F-G score as a criterion for clinical hyperandrogenism or the menstrual cycles' intervals as a criterion for ANOVU, furthermore there are no agreed definition of hyperandrogenism. In our study, clinical hyperandrogenism was determined as mF-G ≥8 and ANOVU was defined as vaginal bleeding episodes at no less than 35-day intervals; some of the other investigators used different cut of points for these definitions [11,14]; e.g. the clinical hyperandrogenism was defined as mF-G ≥6 by Knochenhauer et al. [16] and as mF-G ≥7 DeUgarte et al. [28]. We did not measured the mid luteal phase serum progesterone and it has been shown that 14-40% of eumenorrheic women with androgen excess and 3.7% of eumenorrheic, non hirsute women have oligoovulatory cycles diagnosed by serum concentration of progesterone [24,25,45]. Therefore, the number of ANOVU women in our study might have been increased from 170 to 222 [(205 × 25%) + (423 × 3.7%)] had we assessed mid luteal phase serum progesterone. To verify hyperandrogenemia, we measured serum concentration of all types of androgens among all our participants, regardless of regularity of their menstrual cycles; if serum concentration of androgen was assessed only among women with ANOVU, or if we did

not measure all types of androgens, 8 out of 37 women with only BH would have remain undiagnosed. It seems that the widespread screening of PCOS criteria has a considerable impact on its estimated prevalence at the community level. Recognition of these mild phenotypes of PCOS is a challenging issue and its effectiveness must be evaluated from several perspectives, including the researcher's, clinician's, and the patient's. Azziz et al suggested widespread screening for earlier diagnosis and possibly prevention of serious consequences [46]. However this needs to be confirmed through further well design studies.

The reported prevalence of idiopathic hirsutism varies from 5-29% [19,47]. In the present study, 22.4% of women had only hirsutism, half of them having presented with IH; these women cannot be entirely excluded from the diagnosis of PCOS, because they may have been oligoovulatory, despite of their reported regular episodes of vaginal bleeding [48].

The main strength of the present study is its methodology, as it is a community based prevalence study carried out on an ethnically homogenous population and had an appropriate response rate of 91%. The majority of previous studies on PCOS have relied upon a convenience sample of applicants for university employment [1,16], blood donors [18] or individuals recruited through publicity campaigns [19]. Similar to those reported by Janghorbani et al following a large national survey [49], the educational status and the prevalence of

obesity in the present study could justify and confirm our population as being representative of Iranian reproductive aged women. This study also has the advantage of assessment of androgens in all participants, regardless of their menstrual pattern; hence it was unlikely that any hyperandrogenemic subjects were overlooked. The amount of intra-assay variability in our data is also likely to be minimal because all the laboratory measurements were done at the same laboratory by the same person.

Our study does have some limitations; we did not use the menstrual diary to identify menstrual intervals and we did not measure progesterone to identify eumenorrheic women, who had subclinical menstrual dysfunction; our results may therefore be underestimates; for some cases, socio-cultural constraints precluded a vaginal approach for ultrasonography and as a result a specific and sensitive tool was not used for determining the polycystic ovaries. We did not have any information about those few women who refuse to participate in our study, which may also have affected our estimates.

Conclusions

This study shows that widespread screening of Rotterdam criteria, at the community level, will increase the estimated prevalence of PCOS over twofold. Establishing a clear and contemporaneous method for screening and recognition of PCOS criteria is essential for improving the comparability and potentially the value of published research.

Acknowledgements

We are indebted to each of the study participants for the substantial time and effort contributed to this study. Acknowledgments are also due to the research staff at the health departments of Ghazvin, Kermanshah, Golestan and Hormozgan provinces and personnel of the Research Endocrine Laboratory. My special thanks to Dr. Abedini for her important contribution on research coordination and to Mrs.N.Shiva for editing the manuscript. The authors also thank the National Council of Scientific Research of the I.R.Iran for approval of this project and its funding as a national research project.

Author details

¹Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ²Obesity Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Authors' contributions

FRT contributes in study design, execution, analysis, manuscript drafting and critical discussion. MS contributes in study design, manuscript drafting and critical discussion. MT contributes in study design, laboratory testing and manuscript drafting. FH contributes in analysis, manuscript drafting and critical discussion. FA contributes in study design, execution and manuscript drafting. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 8 January 2011 Accepted: 25 March 2011

Published: 25 March 2011

References

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO: **The prevalence and features of the polycystic ovary syndrome in an unselected population.** *J Clin Endocrinol Metab* 2004, **89**:2745-2749.
2. Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD: **Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria.** *Am J Obstet Gynecol* 2008, **198**(670):e671-677, discussion 670 e677-610.
3. Balen AH, Conway GS, Kaltsas G, Techatrasak K, Manning PJ, West C, Jacobs HS: **Polycystic ovary syndrome: the spectrum of the disorder in 1741 patients.** *Hum Reprod* 1995, **10**:2107-2111.
4. Mulders AG, Laven JS, Eijkemans MJ, de Jong FH, Themmen AP, Fauser BC: **Changes in anti-Mullerian hormone serum concentrations over time suggest delayed ovarian ageing in normogonadotrophic anovulatory infertility.** *Hum Reprod* 2004, **19**:2036-2042.
5. Tehrani FR, Solaymani-Dodaran M, Azizi F: **Is polycystic ovary syndrome an exception for reproductive aging?** *Hum Reprod* 2010, **25**:1775-1781.
6. Navaratnarajah R, Pillay OC, Hardiman P: **Polycystic ovary syndrome and endometrial cancer.** *Semin Reprod Med* 2008, **26**:62-71.
7. Christakou CD, Diamanti-Kandarakis E: **Role of androgen excess on metabolic aberrations and cardiovascular risk in women with polycystic ovary syndrome.** *Womens Health (Lond Engl)* 2008, **4**:583-594.
8. Chun-Sen H, Chien-Hua W, Wan-Chun C, Ching-Tzu L, Chun-Jen C, Ming IH: **Obesity and insulin resistance in women with polycystic ovary syndrome.** *Gynecol Endocrinol* 2010.
9. El-Mazny A, Abou-Salem N, El-Sherbiny W: **Insulin resistance, dyslipidemia, and metabolic syndrome in women with polycystic ovary syndrome.** *Int J Gynaecol Obstet* 2010, **109**:239-241.
10. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS: **Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2004, **89**:5454-5461.
11. March WA, Moore VM, Willson KJ, Phillips DL, Norman RJ, Davies MJ: **The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.** *Hum Reprod* 2010, **25**:544-551.
12. Azziz R: **PCOS: a diagnostic challenge.** *Reprod Biomed Online* 2004, **8**:644-648.
13. Barth JH, Yasmin E, Balen AH: **The diagnosis of polycystic ovary syndrome: the criteria are insufficiently robust for clinical research.** *Clin Endocrinol (Oxf)* 2007, **67**:811-815.
14. Chen X, Yang D, Mo Y, Li L, Chen Y, Huang Y: **Prevalence of polycystic ovary syndrome in unselected women from southern China.** *Eur J Obstet Gynecol Reprod Biol* 2008, **139**:59-64.
15. Goodarzi MO, Quinones MJ, Azziz R, Rotter JI, Hsueh WA, Yang H: **Polycystic ovary syndrome in Mexican-Americans: prevalence and association with the severity of insulin resistance.** *Fertil Steril* 2005, **84**:766-769.
16. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R: **Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study.** *J Clin Endocrinol Metab* 1998, **83**:3078-3082.
17. Michelmore KF, Balen AH, Dunger DB, Vessey MP: **Polycystic ovaries and associated clinical and biochemical features in young women.** *Clin Endocrinol (Oxf)* 1999, **51**:779-786.
18. Asuncion M, Calvo RM, San Millan JL, Sancho J, Avila S, Escobar-Morreale HF: **A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain.** *J Clin Endocrinol Metab* 2000, **85**:2434-2438.
19. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI: **A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile.** *J Clin Endocrinol Metab* 1999, **84**:4006-4011.
20. Farah L, Lazenby AJ, Boots LR, Azziz R: **Prevalence of polycystic ovary syndrome in women seeking treatment from community electrologists. Alabama Professional Electrology Association Study Group.** *J Reprod Med* 1999, **44**:870-874.
21. Kumarapeli V, Seneviratne Rde A, Wijeyaratne CN, Yapa RM, Dodampahala SH: **A simple screening approach for assessing community**

- prevalence and phenotype of polycystic ovary syndrome in a semi-urban population in Sri Lanka. *Am J Epidemiol* 2008, **168**:321-328.
22. Hsu MI, Liou TH, Chou SY, Chang CY, Hsu CS: **Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990.** *Fertil Steril* 2007, **88**:727-729.
 23. Ehrmann DA, Lijlenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN: **Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.** *J Clin Endocrinol Metab* 2006, **91**:48-53.
 24. Azziz R, Waggoner WT, Ochoa T, Knochenhauer ES, Boots LR: **Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama.** *Fertil Steril* 1998, **70**:274-278.
 25. Malcolm CE, Cumming DC: **Does anovulation exist in eumenorrhic women?** *Obstet Gynecol* 2003, **102**:317-318.
 26. Norman RJ, Mahabeer S, Masters S: **Ethnic differences in insulin and glucose response to glucose between white and Indian women with polycystic ovary syndrome.** *Fertil Steril* 1995, **63**:58-62.
 27. Dunaif A, Sorbara L, Delson R, Green G: **Ethnicity and polycystic ovary syndrome are associated with independent and additive decreases in insulin action in Caribbean-Hispanic women.** *Diabetes* 1993, **42**:1462-1468.
 28. DeUgarte CM, Woods KS, Bartolucci AA, Azziz R: **Degree of facial and body terminal hair growth in unselected black and white women: toward a populational definition of hirsutism.** *J Clin Endocrinol Metab* 2006, **91**:1345-1350.
 29. Lookingbill DP, Demers LM, Wang C, Leung A, Rittmaster RS, Santen RJ: **Clinical and biochemical parameters of androgen action in normal healthy Caucasian versus Chinese subjects.** *J Clin Endocrinol Metab* 1991, **72**:1242-1248.
 30. Hatch R, Rosenfield RL, Kim MH, Tredway D: **Hirsutism: implications, etiology, and management.** *Am J Obstet Gynecol* 1981, **140**:815-830.
 31. Pochi PE, Shalita AR, Strauss JS, Webster SB, Cunliffe WJ, Katz HI, Kligman AM, Leyden JJ, Lookingbill DP, Plewig G, et al: **Report of the Consensus Conference on Acne Classification.** Washington, D.C., March 24 and 25, 1990. *J Am Acad Dermatol* 1991, **24**:495-500.
 32. Rosner W, Auchus RJ, Azziz R, Sluss PM, Raff H: **Position statement: Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement.** *J Clin Endocrinol Metab* 2007, **92**:405-413.
 33. Zawadzki JKDA: **Diagnostic criteria for polycystic ovary syndrome: towards a rational approach.** In *Polycystic ovary syndrome*. Edited by: Dunaif A, Givens JR, Haseltine FP, Merriam GR. Boston, MA Blackwell Scientific Publications; 1992.
 34. **The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).** *Hum Reprod* 2004, **19**:41-47.
 35. **ESHRE/ASRM, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome.** *Fertil Steril* 2004, **81**:19-25.
 36. Chiazzze L Jr, Brayer FT, Macisco JJ Jr, Parker MP, Duffy BJ: **The length and variability of the human menstrual cycle.** *JAMA* 1968, **203**:377-380.
 37. Treloar AE, Boynton RE, Behn BG, Brown BW: **Variation of the human menstrual cycle through reproductive life.** *Int J Fertil* 1967, **12**:77-126.
 38. Pache TD, Wladimiroff JW, Hop WC, Fauser BC: **How to discriminate between normal and polycystic ovaries: transvaginal US study.** *Radiology* 1992, **183**:421-423.
 39. Jonard S, Robert Y, Cortet-Rudelli C, Pigny P, Decanter C, Dewailly D: **Ultrasound examination of polycystic ovaries: is it worth counting the follicles?** *Hum Reprod* 2003, **18**:598-603.
 40. Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR: **Androgen excess in women: experience with over 1000 consecutive patients.** *J Clin Endocrinol Metab* 2004, **89**:453-462.
 41. Amini M, Horri N, Farmani M, Haghighi S, Sattari G, Pornaghshband Z, Aminorroaya A: **Prevalence of polycystic ovary syndrome in reproductive-aged women with type 2 diabetes.** *Gynecol Endocrinol* 2008, **24**:423-427.
 42. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC: **PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.** *BJOG* 2006, **113**:1210-1217.
 43. Zhang HY, Zhu FF, Xiong J, Shi XB, Fu SX: **Characteristics of different phenotypes of polycystic ovary syndrome based on the Rotterdam criteria in a large-scale Chinese population.** *BJOG* 2009, **116**:1633-1639.
 44. Lowe P, Kovacs G, Howlett D: **Incidence of polycystic ovaries and polycystic ovary syndrome amongst women in Melbourne, Australia.** *Aust N Z J Obstet Gynaecol* 2005, **45**:17-19.
 45. Carmina E: **Prevalence of idiopathic hirsutism.** *Eur J Endocrinol* 1998, **139**:421-423.
 46. Azziz R, Marin C, Hoq L, Badamgarav E, Song P: **Health care-related economic burden of the polycystic ovary syndrome during the reproductive life span.** *J Clin Endocrinol Metab* 2005, **90**:4650-4658.
 47. McKnight E: **THE PREVALENCE OF "HIRSUTISM" IN YOUNG WOMEN.** *Lancet* 1964, **1**:410-413.
 48. Azziz R, Carmina E, Dewailly D, Diamanti-Kandaraki E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF: **The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report.** *Fertil Steril* 2009, **91**:456-488.
 49. Janghorbani M, Amini M, Willett WC, Mehdi Gouya M, Delavari A, Alikhani S, Mahdavi A: **First nationwide survey of prevalence of overweight, underweight, and abdominal obesity in Iranian adults.** *Obesity (Silver Spring)* 2007, **15**:2797-2808.

doi:10.1186/1477-7827-9-39

Cite this article as: Tehrani et al.: The prevalence of polycystic ovary syndrome in a community sample of Iranian population: Iranian PCOS prevalence study. *Reproductive Biology and Endocrinology* 2011 **9**:39.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

